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Plasmodium parasites infect the liver and replicate
inside hepatocytes before they invade erythrocytes
and trigger clinical malaria. Analysis of host signaling
pathways affected by liver-stage infection could
provide critical insights into host–pathogen interac-
tions and reveal targets for intervention. Using
protein lysate microarrays, we found that Plasmo-
dium yoelii rodent malaria parasites perturb hepato-
cyte regulatory pathways involved in cell survival,
proliferation, and autophagy. Notably, the prodeath
protein p53 was substantially decreased in infected
hepatocytes, suggesting that it could be targeted
by the parasite to foster survival. Indeed, mice that
express increased levels of p53 showed reduced
liver-stage parasite burden, whereas p53 knockout
mice suffered increased liver-stage burden. Further-
more, boosting p53 levels with the use of the small
molecule Nutlin-3 dramatically reduced liver-stage
burden in vitro and in vivo. We conclude that pertur-
bation of the hepatocyte p53 pathway critically
impacts parasite survival. Thus, host pathwaysmight
constitute potential targets for host-based antima-
larial prophylaxis.
INTRODUCTION
Parasites of the genus Plasmodium are the causative agents of
the deadly disease malaria, afflicting 350–500 million people
annually and causing 800,000 deaths worldwide (Snow et al.,
2005). After transmission by an infected Anopheles mosquito,
the parasite travels quickly through the bloodstream to the liver
and infects hepatocytes. The parasite then grows and replicates
within hepatocytes, presumably evading detection by the
host, and ultimately spawns tens of thousands of daughter
merozoites, which are released into the bloodstream and infect
red blood cells, leading to symptomatic infection (Vaughan
et al., 2008).
One feature of host manipulation that has been previously
suggested is the ability of Plasmodium berghei rodent malaria630 Cell Reports 3, 630–637, March 28, 2013 ª2013 The Authorsparasites to render their host hepatocyte partially resistant to
artificial induction of apoptosis in vitro, both early (van de Sand
et al., 2005) and late (Leiria˜o et al., 2005) during liver-stage
development. It remains unclear, however, how broadly the
host hepatocyte responds to infection and if the parasite
attempts to counteract responses that might impact its survival.
One potential mechanism that could explain how parasitized
hepatocytes become resistant to apoptosis involves activation
of the hepatocyte growth factor receptor, but this mechanism
appears unique to the rodent malaria parasite P. berghei
(Carrolo et al., 2003; Kaushansky and Kappe, 2011). Further-
more, some studies have measured transcriptional changes
that occur in P. yoelii and P. berghei-infected hepatocytes
(Albuquerque et al., 2009; Tarun et al., 2008), yet perturbations
in the translational and posttranslational host cell environment
that occur upon parasite liver-stage infection have not been
elucidated.
RESULTS
It remains technically challenging to study protein level cellular
responses to liver-stage infection because infection rates are
low, and thus, infected cells can only be isolated in limited
quantities. To circumvent this roadblock, we used reverse-
phase protein microarray technology, which enables broad
but targeted proteomic investigations on small sample sizes
(Sevecka et al., 2011). The platform uses cellular lysates
deposited in nanoliter droplets on nitrocellulose-coated glass
slides in which levels of specific proteins or their posttransla-
tional modifications can be detected by probing the lysates
with appropriate antibodies (Figure 1A). We assembled
a diverse set of antibodies, many of which have been previ-
ously validated for use in reverse-phase arrays (Sevecka
et al., 2011). These antibodies recognize proteins involved in
numerous cellular outcomes, including survival, apoptosis,
proliferation, cell-cycle control, and autophagy. Approximately
10,000 parasite-infected HepG2/CD81 hepatoma cells as well
as uninfected cells were isolated by fluorescence-activated
cell sorting (FACS), making use of GFP-tagged P. yoelii para-
sites (Tarun et al., 2006). Protein extracts from each sample
were prepared and printed in quadruplicate on 48 separate
nitrocellulose pads followed by probing the arrays with the
selected set of antibodies to obtain quantitative information
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Figure 1. The Use of Protein Microarrays to
Study Host Signaling during Liver-Stage
Malaria Infection
(A) Schematic representing steps required to
obtain lysate microarray data from HepG2/CD81
cells either infected or uninfected with P. yoelii-
GFP liver stages. Liver stages were allowed to
develop for 24 hr. Abs, antibodies.
(B) Representative array images from three anti-
bodies: total p53, LC3A, and p-Akt1/2/3 (pS473).
(C) Graph representing the ratio of infected (GFP-
positive) cells to uninfected (GFP-negative) host
cells for signals obtained for 46 separate anti-
bodies, plotted against the log of the p value ob-
tained. Each point represents a single antibody.
Significant differences that pass multiple hypoth-
esis testing (Holm-Bonferroni method) are shown
in blue; nonsignificant differences are shown in red.
See also Figure S1.on changes in host cell protein abundance and/or modifica-
tions (Table S1; Figure 1C).
Strikingly, the resulting data showed that numerous
signaling proteins are perturbed in parasite-infected cells (Table
S1; Figure 1B). Multiple pathways were simultaneously impacted
at significant but varying levels, indicating that the liver-
stage parasite drives a multipronged approach to modulate
signaling by the infected host cell. When we examined which
signals were most significantly changed in infected cells, we
found pronounced increases in the antiapoptotic-signaling
proteins p-Bcl-2 (p = 0.001) and p-Akt/PKB (p = 0.0008
and p = 0.000003 for two separate antibodies) and the proproli-
ferative phosphorylated states of the mammalian target of
rapamycin (mTor) (p = 0.000008) and Retinoblastoma (Rb)
(p = 0.003) (Table S1). Furthermore, we identified decreases
in phosphorylated forms of the proapoptotic proteins p53
(p = 0.0004) and Bad (p = 0.001 and 0.0002 for two separate
antibodies) as well as a decrease in total abundance of p53
(p = 0.0003 and p = 0.001 for two separate antibodies)
(Table S1; Figure 2A).Cell Reports 3, 630–63Remarkably, these data are consistent
with the hypothesis that a cohesive
network of parasite-mediated-signaling
changes render the infected host cell
more hospitable for the parasite. The
increases of activated Akt and Bcl-2
along with the decrease in Bad indicate
a multifaceted survival response, which
assists the parasite in protecting its host
cell. The increase in mTor suggests
protection against autophagy, which
could severely impede intracellular para-
site development. Activation of Rb
suggests that the infected hepatocyte is
pushed toward a proliferative state.
Finally, the decrease in p53 levels fits
into both the proliferative and antiapop-
totic framework (Figure 2A; Table 1).Together, the observed perturbations are consistent with a
general antiapoptotic, proliferative, antiautophagic environment
within the infected host cell.
Because any screen must be validated with alternative
approaches, we next sought to confirm the major pathways
that were impacted by parasite infection. Both Akt antibodies
have been previously validated in a variety of cell lines, including
HepG2 cells (Luckert et al., 2012). Encouragingly, signal for all
four antibodies in the Akt/mTor pathway recorded increased in
response to parasite infection (Figure S1C). In order to further
validate additional screen hits, we first explored reproducibility
between biological samples, and scalability with data obtained
from immunoblotting. We found that one p53 antibody was
highly reproducible across biological replicates (Figure S1A).
To determine whether this antibody also gave a linear relation-
ship between western blotting and lysate array measurements,
we generated cellular lysates with variable levels of p53 using
a range of concentrations of the MDM-2 inhibitor Nutlin-3.
By monitoring p53 levels in these lysates by both western blot
and lysate array, we determined that the relationship between7, March 28, 2013 ª2013 The Authors 631
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Figure 2. Key Host Signaling Pathways in
Plasmodium Infected Hepatocytes
(A) Schematic showing the connectivity between
host proteins significantly perturbed in liver-stage-
infected cells as measured by protein lysate
microarrays. Proteins for which total level or
posttranslational modifications are increased in
parasitized cells are shown in green, decreased
levels in red. Select antibodies tested demon-
strating a linear relationship between immuno-
blotting (western blotting [WB]) and lysate array
(LA) are colored orange. Proteins for which tran-
scripts where tested and changed are colored
yellow.
(B) Demonstration that total p53 antibody (#9282)
produces a linear relationship for data obtained
using western blotting and lysate array. Data were
fit using a linear regression.
(C) Quantitative PCR showing that transcript levels
of Bad are decreased in infected hepatocytes.
(D) Transcript levels of Bcl-2 are elevated in in-
fected hepatocytes.
Error bars represent SD of analytical replicates.
See also Figure S1.these signals was linear (Figure 2B). Interestingly, whereas total
p53 levels were decreased in infected cells, levels of phosphor-
ylated p53 appeared moderately elevated, suggesting that
residual p53 in infected cells may have altered activity. (Fig-
ure S1D). Additionally, these experiments allowed us to calculate
that the lysate array ratio of 0.82 we observed corresponded to
a decrease of 68% in p53 protein levels in infected cells over
uninfected cells (Figure 2B). In addition to determining the
magnitude of the p53 perturbation in infected cells, these
data highlight a commonly observed feature of lysate array
experiments: the magnitude of changes observed by lysate
arrays is often less pronounced when compared to equivalent
changes observed by alternative means (Figure 2B; Sevecka
et al., 2011).
Overall, signal for antibodies that monitor Bcl-2 phosphoryla-
tion were elevated, whereas antibodies monitoring the Bcl-2
antagonist Bad were diminished in infected cells (Figure S1E).
Of the three antibodies monitoring Bad phosphorylation, which
had statistically significant p values comparing infected and
uninfected samples and also passed the Holm-Bonferroni
test for multiple hypothesis testing, two antibodies showed
diminished Bad levels. To confirm this trend and also to deter-
mine if the effect we observed was regulated on the transcrip-
tional, translational, or posttranslational level, we chose to
assess Bad transcript levels. The results corroborated reduced
Bad levels upon parasite infection because we found Bad tran-
script significantly decreased (p = 0.001) in infected cells. This
also suggested that total Bad levels were decreased rather
than only specific phosphorylated sites (Figure 2C). To validate
the effect of liver-stage parasites on host cell mitochondrial-
signaling proteins, we assessed the transcript levels of Bcl-2,
which, like protein levels, were elevated (p = 0.05) (Figure 2D).
Taken together, we conclude that P. yoelii liver-stage infection632 Cell Reports 3, 630–637, March 28, 2013 ª2013 The Authorsreduces Bad and elevates Bcl-2 transcript abundance as
well as phosphorylated protein abundance in the infected
host cell.
Because of its connectivity with many of the other pathways,
we next chose to probe the functional importance of the host
cell p53 pathway in liver-stage infection. To do this, we first
utilized transgenic mice (called ‘‘super-p53 mice’’) that express
an additional copy of p53 under its endogenous promoter
(Garcı´a-Cao et al., 2002) as well as mice that lack p53 entirely
(‘‘p53 KO mice’’). The levels of p53 increase about 2-fold in the
super-p53 mice because only one additional copy of p53 is
present. When we infected C57BL/6 control mice and super-
p53 mice with P. yoelii sporozoites, then monitored liver-stage
burden, we found that super-p53 mice showed a significantly
reduced liver-stage burden when compared to wild-type mice
(Figure 3A). Next, we utilized p53 KO mice (Jacks et al., 1994)
and predicted that they would be more susceptible to liver-
stage infection. Indeed, p53 KO mice suffered significantly
increased liver-stage burden when compared to wild-type
mice (Figure 3A). This is consistent with our initial finding that
liver-stage parasites are capable of reducing p53 levels in their
host hepatocyte, likely to foster their survival and ensure life
cycle progression. This interference, however, might not reach
its potential maximum (68% reduction of p53 as measured by
lysate arrays of infected cells). By artificially eliminating p53 in
the mouse genome, liver-stage parasites have one less host
defense to combat and are thus even more successful in the
hepatocyte environment.
Although changes in parasite burden observed in p53-trans-
genic mice were consistent with our lysate array findings, we
next asked if more substantial increases in p53 could cause
a more dramatic effect on Plasmodium liver-stage burden. We
took advantage of the small molecule Nutlin-3, which is under
Table 1. Lysate Arrays Demonstrate a Variety of Host Signaling
Proteins that Are Perturbed in Response to Plasmodium Liver-
Stage Infection
Proteins with Most Elevated Levels in Infected Cells versus Uninfected
Cells
Antibody Infected/Uninfected SD p Value
p-Rb (S807/S811) 1.39 0.15 2.21 3 103
p-BCL-2 (S70) 1.26 0.05 1.01 3 103
p-Akt1/2/3 (S473) 1.24 0.06 8.85 3 104
p-mTOR (S2448) 1.21 0.03 7.45 3 106
p-Akt1/2/3 (S473) 1.20 0.03 3.43 3 106
Proteins with Most Reduced Levels in Infected Cells versus Uninfected
Cells
p-BAD (S112) 0.91 0.03 1.25 3 103
p53 0.82 0.04 1.04 3 103
p53 0.74 0.05 2.72 3 104
p-p53 (S15) 0.73 0.09 3.51 3 104
p-BAD (S136) 0.73 0.04 2.28 3 104clinical development for treatment of multiple cancer types
(Brown et al., 2009). Nutlin-3 induces growth arrest and
apoptosis in a variety of cancer cell lines in vitro, including hepa-
toma cell lines (Wang et al., 2011), and is also highly effective in
inhibiting tumor growth in vivo (Vassilev et al., 2004). Nutlin-3
exerts its effects by binding selectively to the p53-binding
region of the E3-ubiquitin ligase MDM-2 and blocks the interac-
tion, which in turn prevents degradation of p53 and, in conse-
quence, increases its protein levels. Interestingly, in our lysate
array analysis, we observed that protein levels of MDM-2 were
increased in response to parasite infection (p = 0.005; Table
S1), indicating that the parasite might promote MDM-2-medi-
ated p53 degradation. We found that the HepG2/CD81 hepa-
toma cell line, which is susceptible to both P. yoelii and
P. berghei infection (Silvie et al., 2003), was responding to Nut-
lin-3 in the predicted fashion because p53 levels were dramati-
cally elevated in response to Nutlin-3 treatment (Figure 3B). To
determine if increased p53 levels affected liver-stage burden,
we treated HepG2/CD81 cells with 20 mM Nutlin-3 before and
after sporozoite infection or only after sporozoite infection.
Each treatment resulted in substantial reduction of liver-stage
burden; however, pre- and postinfection treatment reduced
liver-stage burden more substantially than postinfection treat-
ment alone. (Figures 3C and 3D). Furthermore, remaining liver
stages in Nutlin-3-treated cultures were smaller in size than liver
stages in untreated cultures (Figure S2G). The dramatic
decrease in liver-stage burden after Nutlin-3 treatment was not
caused by off-target effects that directly impacted parasite
fitness because Nutlin-3 treatment had no effect on asexual
blood-stage growth (Figure S2A) or host cell traversal activity
of sporozoites, as measured by a cell-wounding assay (Fig-
ure S2C). Finally, to test if the cellular changes induced by Nut-
lin-3 treatment prior to infection are sufficient to curtail parasite
infection, we treated HepG2/CD81 cells with Nutlin-3 for 24 hr,
washed out the drug, and then infected the cells with sporozo-
ites. A significant decrease in liver-stage burden (Figure S2B)
at 24 hr after infection (Figure S2D) was still observed, furthersupporting the notion that Nutlin-3 interferes with liver-stage
infection by targeting the host cell.
We next hypothesized that, in addition to impacting develop-
ment of liver stages, increased p53 levels due to Nutlin-3 treat-
ment might also contribute to decreased initial infection. To
test this, we pretreated HepG2/CD81 cells with Nutlin-3 and
then measured P. yoelii infection rates at an early time point
(90 min). Interestingly, we observed significantly fewer infected
HepG2/CD81 cells, showing that boosting p53 also alters the
host cells’ susceptibility to initial infection by sporozoites (p =
0.03; Figure 3E). In total, these data indicate that elevated p53
levels render host cells more refractory to initial infection and
also reduce subsequent liver-stage burden.
Finally, to determine if our in vitro findings extended to in vivo
liver-stage infection, we treated BALB/cJ mice with 50 mg/kg
Nutlin-3 once daily for 2 days and infected each mouse with
5 3 104 P. yoelii sporozoites after the first day of treatment. To
confirm that Nutlin-3 had the desired effect of increasing p53
activity in vivo, we also monitored transcript abundance of
p21, a well-characterized positively regulated target of activated
p53, which indeed increased in the liver of Nutlin-3-treated
mice (Figure S2F). The infected mice were sacrificed, and para-
site ribosomal 18S RNA was monitored in their livers by quanti-
tative real-time PCR 24 and 44 hr after infection. We observed
a dramatically lower liver-stage parasite burden in Nutlin-3-
treated mice (Figures 3F and 3G), further supporting the finding
that targeting p53 in the host creates an antiparasitic environ-
ment that curtails parasite liver-stage infection in vivo.
DISCUSSION
We have shown that reverse phase array technology provides
a unique opportunity to probe the perturbations that pathogens
cause in their host cells on the protein level, particularly when it is
not possible to obtain a large number of infected cells. Our
analysis of malaria parasite liver-stage infection suggests that
Plasmodium parasites select for, and/or shape, a hepatocytic
environment that is proproliferative, antiapoptotic, and antiauto-
phagic. Some of our findings are supported by previous work
showing that liver-stage-infected cells are resistant to at least
some apoptotic stimuli (van de Sand et al., 2005). In addition, it
was shown that that inhibition of the proliferative PI3K/Akt
pathway can reduce liver-stage infection (Leiria˜o et al., 2005),
further reinforcing our findings. However, the broad changes in
the signaling environment of the infected hepatocyte have re-
mained elusive. Although several of the pathways we identified
must be further interrogated for precise mechanism of action,
our data lay the framework for a more thorough understanding
of host–pathogen interactions that the malaria parasite has
evolved for successful replication in hepatocytes.
Specifically, our findings demonstrate that p53 is a key
host cell signaling node perturbed by the parasite, whose
regulation is critical to successful liver-stage infection. Liver-
stage parasites significantly but incompletely suppress host
p53, thus increasing survival of the infected cell. However,
pharmacological or genetic boosting of p53, which the para-
site has not encountered throughout its evolution, counteracts
this suppression and impedes parasite proliferation. Conversely,Cell Reports 3, 630–637, March 28, 2013 ª2013 The Authors 633
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Figure 3. Transgenic Mice and Pharmacological Perturbations Demonstrate a Critical Role for Host p53 in Liver-Stage Infection
(A) Mice with an additional copy of p53 (super-p53mice) (n = 13), without p53 (p53 KOmice) (n = 7), or wild-type C57BL/6mice (n = 20) were infected with 100,000
P. yoelii sporozoites. Liver-stage burden was monitored 42–44 hr after infection using quantitative reverse-transcription PCR. Parasite burden was significantly
reduced in super-p53 mice (p = 0.004) and significantly elevated in p53 KO mice (p = 0.04).
(B–D) p53 levels increase in response to 48 hr Nutlin-3 treatment, as demonstrated by western blot using an anti-p53 antibody (B). An anti-a-tubulin antibody was
used as a loading control. Nutlin-3 treatment (20 mM) 24 hr before and during infection (pre and post) dramatically reduces liver-stage burden of P. yoelii
(C, middle) andP. berghei (D, middle). When treatment is applied beginning at time of infection and continuing until 24 hr after infection (post), liver-stage burden is
also reduced, albeit less substantially for both P. yoelii (C, right) and P. berghei parasites (D, right). All liver stages were quantified 24 hr postinfection in HepG2/
CD81 cells. Error bars represent SD between biological replicates.
(E) To monitor the effects of Nutlin-3 on P. yoelii (Py) sporozoite infection of HepG2/CD81 cells, cells were trypsinized 90 min postinfection, fixed, stained with an
antibody to CSP, and subjected to flow cytometric analysis. Wells that were not infected with sporozoites were used as a control. Error bars represent SD of
biological replicates.
(legend continued on next page)
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removing p53 genetically provides the parasite with a more
hospitable environment for development. Consistent with
this, we find no evidence that malaria parasites lower p53
levels to a degree that promotes host cell transformation, as
has been described for the related apicomplexan parasite
Theileria (Haller et al., 2010). However, the long-term conse-
quences of hepatocyte infection cannot be observed because
infected cells die during parasite egress from the liver (Sturm
et al., 2006).
The pleotropic functions of p53 in cellular signaling suggest
a number of mechanisms for its role during liver-stage infection.
Diminishing levels of p53 in the host hepatocyte could be an
obvious advantage for Plasmodium survival because low p53
levels are a major player in developing hepatocyte resistance
to apoptosis (Eferl et al., 2003). Although p53 also mediates
cell-cycle arrest, to date, there has been no evidence that para-
sites prefer or benefit from actively cycling host cells. Finally, our
finding that elevated levels of p53 not only have a deleterious
effect on liver-stage development but also on initial sporozoite
infection suggests that p53 affects multiple factors influencing
pre-erythrocytic parasite life cycle progression. These could
include the modulation of hepatocyte receptors affecting sporo-
zoite invasion and changes to the hepatocyte cytoskeleton,
which could affect liver-stage growth.
The roles of p53 in both cell-cycle arrest and apoptosis are
well understood. However, striking recent evidence suggests
that the most dramatic cellular outcomes mediated by p53 func-
tion can occur independently of these roles (Li et al., 2012) and
that p53 has a substantial role in modulating cellular metabolism
and the regulation of reactive oxygen species. These alternatives
suggest enticing hypotheses to explain the role of p53 in control-
ling liver-stage parasite development. Plasmodium parasites
undergo rapid growth during liver-stage infection, suggesting
a significant metabolic requirement. Future studies will fully
elucidate the interplay between host p53 levels and liver-stage
parasite survival.
Insights into the host cell-signaling milieu that promotes liver-
stage survival critically inform host–pathogen interaction studies
but might also present potential opportunities for prophylaxis.
Efforts to pharmacologically target malaria parasites have
focused on intrinsic parasite pathways that are prone to the
development of drug resistance (Fidock, 2010; Mackinnon and
Marsh, 2010). Here, we demonstrate that the parasite dampens
detrimental host signaling, while boosting prosurvival and prolif-
erative signaling. These changes in host signaling represent key
features in the intracellular environment required for efficient
parasite development. Accordingly, perturbed nodes also repre-
sent points of susceptibility. More specifically, Nutlin-3 greatly
elevates p53 levels and thus dramatically diminishes liver-stage
parasite burden. Encouragingly, Nutlin-3 has been used in early
clinical trials for cancer indications (Secchiero et al., 2011), sug-
gesting that a host-based prophylaxis approach for malaria(F andG) Nutlin-3 treatment dramatically reduces liver-stage burden inmice. A tota
At the time of the last administration of Nutlin-3, mice were infected with 50,000 P
and parasite 18S ribosomal RNA was assessed by quantitative real-time PCR. S
represented by a horizontal line, and the level of Py18S/GAPDH is shown for eac
See alsoFigure S2.control could be readily translatable to clinical studies. Host-tar-
geted interventions, capable of blocking infection and elimi-
nating the parasite in the liver, are worthy of investigation as
a new avenue for antimalarial prophylaxis.
EXPERIMENTAL PROCEDURES
Isolation of PyGFP-Infected HepG2/CD81 Cells
Cells were cultured as described in Extended Experimental Procedures. A
total of 5 3 106 cells were infected with 2 3 106 P. yoelii transgenic parasites
that express GFP as described previously by Tarun et al. (2008). Cells were
detached using 0.25% Trypsin-EDTA and resuspended in DMEM Complete
with 5 mM EDTA. Cells were passed through a cell strainer to prepare for
FACS. Flow cytometric analyses and cell sorting of PyGFP-infected hepato-
cytes were carried out with a Cytopeia Influx Cell Sorter using the Spigot
Operating Software Version 5.0.3.1 (Cytopeia).
Microarray Fabrication
Cells were lysed in SDS lysis buffer (2% SDS, 50 mM Tris-HCl, 5% glycerol,
5 mM EDTA, 1 mM NaF, 10 mM b-glycerophosphate, 1 mM PMSF, 1 mM
activated Na3VO4, 1 mM DTT, 1% phosphatase inhibitor cocktail 2; Sigma-
Aldrich), 1% PhosSTOP Phosphatase Inhibitor Cocktail Tablet (Roche),
and stored at 80C. Custom lysate microarrays were printed in-house
using an Aushon Biosystems 2470 arrayer (Aushon Biosystems) on 16-pad
nitrocellulose-coated glass slides (Grace Bio-Labs). Lysates were arrayed at
333 mM spacing using solid 110 mM pins, which resulted in an average feature
diameter of 170 mM. Lysates were arrayed in quadruplicate technical repli-
cates. Slides were then stored dry, in the dark, and at room temperature until
probing. Slides were probed and quantified as previously described by
Sevecka et al. (2011).
Quantification of p53 by Western Blotting
We plated 106 HepG2/CD81 cells in each well of a 6-well plate in
DMEM Complete and treated with 20 mM Nutlin-3 (Cayman Chemical).
We made cellular lysates with SDS array buffer (described above). Western
blots were performed according to standard protocols using an antibody to
p53 (Clone 1C12; Cell Signaling Technology) then normalized to signal
from an anti-a-tubulin (Invitrogen) Western blot. Signals from immunoblots
were detected using either an Alexa 680-conjugated anti-rabbit antibody
or an Alexa 800-conjugated anti-mouse antibody (LI-COR Biosciences). We
visualized membranes using an Odyssey infrared imaging system (LI-COR
Biosciences).
Immunofluorescence
A total of 105 HepG2/CD81 cells were infected with 104 P. berghei or P. yoelii
sporozoites as previously described. Cells were fixed and stained as
described previously (Kaushansky and Kappe, 2011). We stained cells using
antisera to Plasmodium heat shock protein 70 (hsp70) upregulated in infec-
tious sporozoite 4 protein (UIS4). Sporozoites that had not invaded and/or
developed in hepatoma cells were distinguished by UIS4 noncircumferential
staining and morphology.
Quantification of Liver Stages after Nutlin-3 Treatment by Manual
Counting
A total of 105 HepG2/CD81 cells were treated with DMSO alone or 20 mM
Nutlin-3 for the indicated period of time. Cells were infected with 104
P. berghei or P. yoelii sporozoites. Parasites were stained and visualized as
described above. All liver stages in each well were counted, and each assay
was performed in biological triplicate.l of 50mg/kg Nutlin-3was administered once daily for 2 days to BALB/cJmice.
. yoelii sporozoites. Livers were removed at 24 hr (F) or 44 hr (G) postinfection,
ignal was normalized to mouse GAPDH. For in vivo experiments, the mean is
h individual mouse.
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Quantification of Liver Stages by FACS
Cells were cultured as described above. A total of 2 3 105 HepG2/CD81 cells
were plated in each well of a 24-well plate and infected with 5 3 104 P. yoelii
sporozoites. Cells were treated with or without Nutlin-3 as described above.
At the desired time point, cells were harvested and stained as described previ-
ously by Luckert et al. (2012). All experimental conditionswere tested in biolog-
ical triplicate. All data are representative of three independent experiments.
Cell-Wounding Assay
A total of 105 HepG2/CD81 cells were plated into each well of a 48-well plate
and allowed to adhere overnight in DMEM Complete. We mixed 5 3 104
P. yoelii sporozoites, or media alone with 1 mg/ml Alexa Fluor 488-labeled
dextran (10,000 MW, lysine fixable; Invitrogen), then performed the traversal
assays as described previously by Luckert et al. (2012). Wounded cells (iden-
tified by positive Alexa Fluor 488 signal) were analyzed by FACS.
In Vivo Nutlin-3 Experiments
A total of 26 BALB/cJmice (Jackson) were treatedwith either vehicle control or
50 mg/kg of Nutlin-3 once daily for 2 days. On the second day of treatment,
mice were injected with 5 3 104 P. yoelii sporozoites. Livers were excised
from mice at either 24 or 44 hr after infection. Animal handling was conducted
according to Institutional Animal Care and Use Committee-approved
protocols.
Super-p53 and p53 KO Mice Experiments
A total of 20 male C57BL/6 (Jackson), 13 C57BL/6-super-p53, and 7 C57BL/
6-p53-KO (Jackson) mice were injected with 105 P. yoelii-GFP-luciferase
sporozoites. At 42–44 hr postinfection, livers were excised from mice and
lysedwith TRIzol reagent (Invitrogen). Animal handling was conducted accord-
ing to Institutional Animal Care and Use Committee-approved protocols.
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